Results 41 to 50 of about 3,869 (167)

Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials

Critical Care, 2017
Background Small trials suggest that levosimendan is associated with a favorable outcome in patients undergoing cardiac surgery. However, recently published larger-scale trials did not provide evidence for a similar benefit from levosimendan.
Qi-Hong Chen, Rui-Qiang Zheng, Hua Lin, Jun Shao, Jiang-quan Yu, Hua-Ling Wang   +5 more
doaj   +1 more source

The effects of levosimendan in patients undergoing transcatheter aortic valve replacement- a retrospective analysis

Frontiers in Pharmacology, 2022
Background: Aortic stenosis (AS) increases left ventricular afterload, leading to cardiac damage and heart failure (HF). Transcatheter aortic valve replacement (TAVR) is an effective therapy for AS.
Zhenyan Zhao, Zhen Meng, Zhen Meng, Guangyuan Song, Chunrong Wang, Sheng Shi, Jie Zhao, Hongliang Zhang, Moyang Wang, Guannan Niu, Zheng Zhou, Jianhui Wang, Yongjian Wu   +12 more
doaj   +1 more source

Biventricular Impella Support for Ventricular Tachycardia Ablation in a Patient With Severe Dilated Cardiomyopathy

Clinical Case Reports, Volume 14, Issue 3, March 2026.
VT ablation with percutaneous biventricular Impella support in a patients with non‐ischemic dilated cardiomyopathy and severe biventricular failure. Segmented Inheart CT, angulation a.p. (a) and LAO (c). Segmentation revealed the prior ablation site (blue arrow) and extensive intramural fibrotic tissue (asterisk).
Madeleine Tydecks, Theresa Reiter, Gabriele Hessling, Isabel Deisenhofer, Mohammad Al Fayad   +4 more
wiley   +1 more source

Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review

European Cardiology Review
Cardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated.
Hendri Susilo, Fan Maitri Aldian, Citrawati Dyah Kencono Wungu, Mochamad Yusuf Alsagaff, Henry Sutanto, Chaq El Chaq Zamzam Multazam   +5 more
doaj   +1 more source

Practical considerations for the use of vericiguat in older patients with heart failure and reduced ejection fraction

European Journal of Clinical Investigation, Volume 56, Issue 2, February 2026.
Vericiguat represents an optimal therapeutic option for older patients with heart failure with reduced ejection fraction (HFrEF). It possesses several advantages: once daily dosing, favourable tolerability, reassuring safety and limited drug–drug interactions.
Francesco Castelletti, Elena Bianco, Giulia Fabro, Eleonora Nicolini, Francesco Dentali, Luca Liberale, Flavio Tangianu, Aldo Bonaventura   +7 more
wiley   +1 more source

Renoprotective effects of levosimendan on acute kidney injury following cardiac arrest via anti‐inflammation, anti‐apoptosis, and ERK activation

FEBS Open Bio, 2021
ATP‐sensitive potassium channels (KATPs) have protective effects in ischemia–reperfusion‐induced injuries and can be activated by levosimendan. This study investigated the effects of levosimendan on renal injury, inflammation, apoptosis, and survival in ...
Lei Tian, Shiwei Wang, Li Zhao, Xiaoye Lu, Changqing Zhu, Hao Gong, Weiqiang Yang   +6 more
doaj   +1 more source

Hemodynamic‐Driven Staging of Heart Failure With Preserved Ejection Fraction Using Unsupervised Cluster Analysis

Pulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Invasive exercise hemodynamics are used to diagnose heart failure with preserved ejection fraction (HFpEF), based on pulmonary artery wedge pressure (PAWP) or left atrial (LA) pressure elevations. We hypothesized that applying unsupervised cluster analysis to comprehensive hemodynamic characterization might provide data‐driven phenotypes, with
Sergio Caravita, Claudia Baratto, Céline Dewachter, Veraprapas Kittipibul, Giovanni Battista Perego, Fabio Previdi, Stefano Paleari, Mattia Cattaneo, Luigi P. Badano, Michele Senni, Marat Fudim, Gianfranco Parati, Jean‐Luc Vachiéry, Ettore Lanzarone   +13 more
wiley   +1 more source

İleri kalp yetersizliği hastalarında levosimendanın eritrosit dağılım genişliği üzerine etkisi

Genel Tıp Dergisi, 2015
Amaç: Levosimendan dekompanse kalp yetersizliğinde kullanılan, olumlu hemodinamik etkileri de olan pozitif inotropik bir ilaçtır. Bu çalışmanın amacı levosimendan tedavisi almış ileri kalp yetersizliği hastalarının tedavi öncesi ve sonrası eritrosit ...
Ahmet Gürel, Niyazi Güler, Murat Aydın, Şeref Alpsoy, Aydın Akyüz, Dursun Çayan Akkoyun   +5 more
doaj  

Does Levosimendan hasten veno-arterial ECMO weaning? A propensity score matching analysis

Annals of Intensive Care
Background Preliminary evidence from small, single-center studies suggests levosimendan may improve the likelihood of successful venoarterial extracorporeal membrane oxygenation (VA-ECMO) weaning in patients with cardiogenic shock.
Nicolas Paulo, Antoine Kimmoun, David Hajage, Pierre Hubert, David Levy, Marc Pineton de Chambrun, Juliette Chommeloux, Ouriel Saura, Grégoire Del Marmol, Quentin Moyon, Guillaume Hékimian, Melchior Gautier, Charles Edouard Luyt, Guillaume Lebreton, Bruno Levy, Alain Combes, Matthieu Schmidt   +16 more
doaj   +1 more source

Inhibition of reverse-mode sodium-calcium exchanger activity and apoptosis by levosimendan in human cardiomyocyte progenitor cell-derived cardiomyocytes after anoxia and reoxygenation. [PDF]

PLoS ONE, 2014
Levosimendan, a known calcium sensitizer with positive inotropic and vasodilating properties, might also be cardioprotective during ischemia-reperfusion (I/R) insult. Its effects on calcium homeostasis and apoptosis in I/R injury remain unclear. Na(+)/Ca(
Ping-Chun Li, Ya-Chi Yang, Guang-Yuh Hwang, Lung-Sen Kao, Ching-Yuang Lin   +4 more
doaj   +1 more source